Startups
Opterion Health is focused to bring innovation to dialysis and foster peritoneal dialysis (PD). The company aims to improve the quality of life for patients as well as their loved ones and to possibly increase the survival rates of people who suffer from chronic kidney disease (CKD).
Opterion Health was founded in 2012 by healthcare experts. The Company, based in Switzerland, is one of the few research-driven companies developing a novel PD solution. Opterion Health is privately held and financed by Angel Investors.
The new Opterion dialysis solution is the first innovation in PD in the last two decades and will not only improve patients’ well-being by offering flexibility at work and at home, but also reduce dialysis-related healthcare costs.
The new PD solution is glucose-free, considerably decreasing metabolic challenges and offers an innovative dialysis option for those patients who suffer from diabetes (approx. 45% of dialysis patients).
Opterion Health is a pure play PD Company with two novel approaches in development, based on known molecules. Our two-fold approach will increase the medical utility of PD by offering a better osmotic driver (ODR) and – possibly in combination – a biocompatibility-enhancing agent (BCA).
Opterion Health was founded in 2012 by healthcare experts. The Company, based in Switzerland, is one of the few research-driven companies developing a novel PD solution. Opterion Health is privately held and financed by Angel Investors.
The new Opterion dialysis solution is the first innovation in PD in the last two decades and will not only improve patients’ well-being by offering flexibility at work and at home, but also reduce dialysis-related healthcare costs.
The new PD solution is glucose-free, considerably decreasing metabolic challenges and offers an innovative dialysis option for those patients who suffer from diabetes (approx. 45% of dialysis patients).
Opterion Health is a pure play PD Company with two novel approaches in development, based on known molecules. Our two-fold approach will increase the medical utility of PD by offering a better osmotic driver (ODR) and – possibly in combination – a biocompatibility-enhancing agent (BCA).
Overview
Location
Switzerland
Employees
1-10
Total raised
$17.44M
Founded date
2012
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jan 21, 2021 | Funding round | $10.22M |
Mentions in press and media 13
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 25, 2026 | Three Swiss biotechs promote from within | Lausanne-based Avrion Therapeutics, an EPFL spin-off founded in 2020, has appointed co-founder Maximilien Murone as interim Chief Executive Officer in June. He succeeds Harald Petry, who has led the preclinical-stage biotech since 2022 and... |
| Mar 10, 2026 | Three Swiss medtechs launch clinical studies | Basel-based Qnomx, founded in 2020, is a GenAI platform designed to ease the interpretation of cancer genome data. The company has kicked off its clinical performance study with Vall d’Hebron Institute of Research in Barcelona. Genomics is... |
| Dec 8, 2025 | Executive hires for four startups | EvlaBio, the startup developing novel antibody therapeutics for cardiorenal diseases specifically addressing Left Ventricular Hypertrophy (LVH) in the setting of chronic kidney disease, has appointed Christian Stegmann as Chief Scientific ... |
| Sep 21, 2023 | Opterion raises CHF 6.5m in an oversubscribed financing round | |
| Sep 20, 2023 | Opterion Health closes oversubscribed financing round, securing CHF 6.5m, and announces changes to its Board of Directors | Opterion Health closes oversubscribed financing round, securing CHF 6.5m, and announces changes to its Board of Directors Wed, Sep 20, 2023 10:25 CET Report this content Opterion Health secures CHF 6.5m commitments to fund ongoing preclinic... |
| Feb 14, 2023 | New executives to drive local and international growth | |
| Jan 18, 2023 | Opterion Health appoints Peter Reinemer as CEO | Opterion Health appoints Peter Reinemer as CEO Wed, Jan 18, 2023 09:09 CET Report this content Muttenz, Switzerland, 18 January 2023 – Opterion Health AG, a Swiss-based life sciences company developing the first major innovation in peritone... |
| Sep 16, 2021 | Opterion Health strengthens its Management Team | Opterion Health strengthens its Management Team Thu, Sep 16, 2021 10:13 CET Muttenz, Switzerland, 16 September 2021 – Opterion Health AG, a nephrology company focused on innovation in Peritoneal Dialysis (PD), today announced a significant ... |
| Mar 26, 2021 | Four startups announce senior leadership appointments | Effective April, Roger Hall will take over as CEO of UniqFEED, the Swiss virtual advertising provider. Hall is a leading management consultant with more than 20 years of experience in the media, technology, broadcasting, and sports sectors.... |
Show more
Reviews 0
FAQ about Opterion Health AG
When was Opterion Health AG founded?
Opterion Health AG was founded in 2012.
How much funding has Opterion Health AG raised?
Opterion Health AG has raised $17.44M in total across 2 funding rounds.
What funding rounds has Opterion Health AG raised?
Parsers VC lists 2 funding rounds of Opterion Health AG, among them a funding round of $10.22M on Jan 21, 2021.
What has the press written about Opterion Health AG?
Parsers VC has collected 13 articles mentioning Opterion Health AG, among them “Three Swiss biotechs promote from within” (Aug 25, 2026) and “Three Swiss medtechs launch clinical studies” (Mar 10, 2026).
Is Opterion Health AG still active?
Yes, Opterion Health AG is active; its latest activity on Parsers VC dates from Sep 23, 2026.